Other/Multi-Tumor | Pfizer Medical Information

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.

Back to Diseases Areas

Poster

Adams CR, Wang TS, Wang L, Miller N, McMillan E, Ramstetter M, Chionis J, Eisele K, Almaden J, Affolter T, Pillai S, Dann SG, Dillon C, VanArsdale T April 10, 2021 AACR 2021 Other/Multi-Tumor

A novel mouse model of pancreatic cancer reveals new insights into cell cycle deregulation

View Presentation

Poster

Wang TS, Almaden J, Shen C, Lapek J, Niessen S, Miller N, Dann S, VanArsdale T April 10, 2021 AACR 2021 Other/Multi-Tumor

Identifying synthetic lethality with novel CDK2 small molecule inhibitors via integration of high-content microscopy and –omics level platforms

View Presentation

Poster

Wager K, Chari D, Ho S, Rees T, Schijvenaars RJA April 10, 2021 AACR 2021 Other/Multi-Tumor

Navigating Networks of Oncology Biomarkers Mined from the Scientific Literature: A New Open Research Tool

View Presentation View Abstract Plain Language Summary

Poster

Bouhana K, Anderson D, DeWolf W, Brown S, Ren L, Moreno D, Fell B, Wallace R, Williams L, Hartley D, Lee P April 10, 2021 AACR 2021 Other/Multi-Tumor

Nonclinical development of PF-07284890 (ARRY-461), a potent, brain-penetrant, small molecule inhibitor of BRAFV600-mutation-driven tumors in vitro and in vivo

View Presentation

Poster

Wong J, Harrison J, Bouhana K, Nguyen N, Shaabani N, Vartabedian VF, Cable L, Rieger R, Opie LP, Laird ER, Allen S, Cook A, Dahlke J, McNulty OT, Barbour PMD, Hinklin R, Chantry D, Winski S, Teijaro J April 10, 2021 AACR 2021 Other/Multi-Tumor

The potent and selective MERTK/AXL inhibitor PF-5807/ARRY-067 activates dendritic cells to cross-prime CD8+ T cells for anti-tumor activity

View Presentation

Oral Presentation

Yang J, Blinzler K, Lankin J, Maculaitis M, Shelbaya A May 17, 2021 ISPOR 2021 Other/Multi-Tumor

Patterns of Utilization and Implementation Experiences of Oncology Monoclonal Antibodies (MAbs) Biosimilars in the U.S.: From Both Payers and Healthcare Professionals (HCPs) Perspectives

View Presentation

Poster Discussion

Grisham, Vergote, Banerjee, Drill, Fabbro, Mirza, Romero, Coleman, Oza, Hilpert, Moore, Westermann, Aghajanian, Scambia, Canty-Kiser, O’Malley, Farley, Colombo, Monk June 4, 2021 ASCO 2021 Other/Multi-Tumor

Molecular Results and Potential Biomarkers Identified from the MILO/ENGOT-ov11 Phase 3 Study of Binimetinib vs Physicians Choice of Chemotherapy (PCC) in Patients with Recurrent Low-Grade Serous Ovarian Cancer

View Presentation

Poster

Subbiah V, Gutierrez M, Anders CK, Ansstas G, Owonikoko TK, Monga V, Forsyth P, Dagogo-Jack I, Chandra S, Tsai KK, Diamond EL, McKean MA, Buchbinder E, Nepert D, Ingram K, Oliver C, Reddy M, Maharry K, Xing Y June 4, 2021 ASCO 2021 Other/Multi-Tumor

Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors

View Presentation View Abstract Plain Language Summary

Poster

Subbiah V, Awad M, Daud A, Gutierrez M, McDermott J, Ou SH I, Hirohashi T, Ingram K, Oliver C, Smith D, Wollenberg L, Abbruzzese J June 4, 2021 ASCO 2021 Other/Multi-Tumor

Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors

View Presentation View Abstract Plain Language Summary

Poster

Rodon Ahnert J, Perez C, Wong K, Maitland M, Tsai F, Berlin J, Liao K, Wang IM, Markovstrova L, Jacobs I, Cavazos N, Li M, Tolcher A June 6, 2021 ASCO 2021 Other/Multi-Tumor

PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: a Phase 1 dose escalation study

View Presentation View Abstract Plain Language Summary

Congress Materials